share_log

西南证券4月16日发布研报称，给予九洲药业（603456.SH）买入评级。评级理由主要包括：1）业绩符合预期，CDMO板块实现稳健增长；2）多肽及偶联药物、制剂平台等新业务能力建设初见成效。（每日经济新闻）

Southwest Securities released a research report on April 16 stating that it gave Jiuzhou Pharmaceutical (603456.SH) a purchase rating. The main reasons for the rating include: 1) the performance was in line with expectations, and the CDMO sector achieved

Zhitong Finance ·  Apr 16 19:09
Southwest Securities released a research report on April 16 stating that it gave Jiuzhou Pharmaceutical (603456.SH) a purchase rating. The main reasons for the rating include: 1) the performance was in line with expectations, and the CDMO sector achieved steady growth; 2) capacity building for new businesses such as peptides, conjugated drugs, and formulation platforms is beginning to bear fruit. (Mainichi Keizai Shimbun)

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment